Polymorphic and other crystalline forms of cis-FTC

Details for Australian Patent Application No. 2002335489 (hide)

Owner Abbott Laboratories Gilead Sciences, Inc

Inventors Law, Devalina; Phares, Kenneth R.; Hu, Yuerong

Agent Davies Collison Cave

Pub. Number AU-B-2002335489

PCT Number PCT/US02/06184

PCT Pub. Number WO2002/070518

Priority 60/272,560 01.03.01 US; 60/309,605 02.08.01 US

Filing date 1 March 2002

Wipo publication date 19 September 2002

Acceptance publication date 5 June 2008

International Classifications

C07D 411/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms

A61K 31/513 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

A61P 1/16 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 31/18 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 31/20 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

13 February 2003 Complete Application Filed

  Priority application(s): 60/272,560 01.03.01 US; 60/309,605 02.08.01 US

13 March 2003 Application Open to Public Inspection

  Published as AU-B-2002335489

17 June 2004 Assignment before Grant

  Abbott Laboratories; Triangle Pharmaceuticals, Inc. The application has been assigned to Abbott Laboratories; Gilead Sciences, Inc.

24 June 2004 Corrigenda

  Assignments Before Grant, Section 113 - 2002 Under the name Abbott Laboratories, Gilead Sciences, Inc., delete all reference to Application No. 2002335489 Specifications Republished The following specifications contained errors when advertised OPI, Accepted or Certified. They have been reissued on the AU-A or AU-B CD-ROM of this Journal date. 2002300001 Benfranca Nominees Pty Ltd 2002300225 Canon Kabushiki Kaisha

22 May 2008 Assignment before Grant

  Abbott Laboratories; Triangle Pharmaceuticals, Inc. The application has been assigned to Abbott Laboratories; Gilead Sciences, Inc

5 June 2008 Application Accepted

  Published as AU-B-2002335489

2 October 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002335490-Peptide deformylase inhibitors

2002335488-RADIO COMMUNICATION DEVICE